# OnCo record arcellx (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/arcellx/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "arcellx" ;
  schema:name "Arcellx"@en ;
  schema:description "Arcellx developed anito-cel, a CAR T-cell therapy for multiple myeloma that reprogrammes a patient's own immune cells to attack a marker called BCMA. Gilead bought the company in 2026 for about $7.8 billion ahead of a possible US approval."@en ;
  schema:url <https://onco.cc/companies/arcellx/>, <https://www.kitepharma.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.kitepharma.com/>, <https://www.kitepharma.com/news/press-releases/2026/2/gilead-sciences-to-acquire-arcellx-to-maximize-long-term-potential-of-anito-cel>, <https://www.kitepharma.com/news/press-releases/2026/4/gilead-sciences-completes-acquisition-of-arcellx-ahead-of-potential-commercial-launch-of-anito-cel>, <https://www.sec.gov/Archives/edgar/data/1786205/000119312522032077/d303972dex991.htm> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/> ;
  onco:technologies <https://onco.cc/technologies/car-t/> ;
  onco:targets <https://onco.cc/targets/bcma/> .